• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

    6/14/24 4:54:19 PM ET
    $ASLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares.

    For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the Company's ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected to take place at the opening of trading on July 3, 2024 (U.S. Eastern Time). ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of every eight (8) then-held (old) ADSs for one (1) new ADS will occur automatically with the then-held (old) ADSs being cancelled and new ADSs being issued by the depositary bank, in each case as of the effective date for the ADS ratio change, July 3, 2024. The ADSs will continue to be traded on Nasdaq under the symbol "ASLN".

    No fractional new ADSs will be issued in connection with the ADS ratio change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank.

    As a result of the ADS ratio change, the ADS price is expected to increase proportionally, although the Company can give no assurance that the trading price of the Company's ADS price after the ADS ratio change will be equal to or greater than eight (8) times the ADS price before the ADS ratio change.

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn.

    Forward looking statements

    This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to, statements regarding the trading price of the Company's ADSs. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; risks that future clinical trial results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials; clinical site activation rates or clinical trial enrollment rates that are lower than expected; the impact of health epidemics or pandemics, or geopolitical conflicts on the Company's operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers and collaborators with whom the Company conducts business; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 12, 2024. All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6206 7350

    Email: [email protected]

    Ashley R. Robinson

    LifeSci Advisors, LLC

    Tel: +1 (617) 430-7577

    Email: [email protected]   


    Primary Logo

    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN

    DatePrice TargetRatingAnalyst
    7/9/2021$8.00Buy
    Jefferies
    More analyst ratings

    $ASLN
    Leadership Updates

    Live Leadership Updates

    See more
    • ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

      New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p

      3/6/24 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

      - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President

      3/15/22 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

      MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

      12/6/21 7:00:00 AM ET
      $ASLN
      $IQV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

      Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper

      7/17/24 7:25:04 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

      SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff

      7/15/24 7:30:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

      SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C

      6/14/24 4:54:19 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/21/24 4:42:13 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/19/24 4:30:30 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

      SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      2/14/24 4:45:26 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited

      25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      9/6/24 7:41:52 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited

      SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      8/8/24 11:36:38 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ASLAN Pharmaceuticals Limited

      6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)

      7/17/24 7:29:55 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

      Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      7/9/21 7:45:23 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously

      3/17/21 6:40:11 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Financials

    Live finance-specific insights

    See more
    • ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

      - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology

      9/27/21 6:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care